Sirona Announces Results of Shareholder Meeting

VANCOUVER, BC--(Marketwired - June 10, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") is pleased to announce that all resolutions tabled at its Annual General and Special Meeting held on June 10, 2014, were passed. The resolutions included:

• Election of Geraldine Deliencourt-Godefroy, Christopher Hopton, Alex Marazzi, David Moore, Michael Rogers, Nigel Terrett and Howard Verrico as directors;
• Appointment of auditor and authorization of the directors to fix the auditor's remuneration;
• Adoption of a 2014 Stock Option Plan;
• Adoption of new Articles of the Company.

The new Articles will bring the Company up to date with current corporate practices, including incorporating advance notice provisions with respect to election of directors (the "Advance Notice Provisions"). The Advance Notice Provisions will ensure an orderly nomination process of directors, ensure that shareholders are well-informed about the identity, intentions and credentials of director nominees and ensure that shareholders vote in an informed manner after having been afforded reasonable time for appropriate deliberation.

The new Articles are available on SEDAR under the Company's profile and shareholders are encouraged to review the Articles in their entirety.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.